

connection

important information for fallon community health plan physicians and providers

july 2008

● every day affairs

fchp welcomes new chief medical officer

Elizabeth Malko, M.D., has been appointed the new Chief Medical Officer for Fallon Community Health Plan. Barbara Chase, M.D., who has served as interim Chief Medical Officer, has been appointed Senior Medical Director.



Dr. Malko comes to FCHP from WellPoint, Inc., where she was East Regional Medical Director. She previously served as Medical Director for Anthem Blue Cross and Blue Shield in New Hampshire and Connecticut. She has provided extensive direction and leadership in medical and pharmaceutical management, quality of care initiatives and disease state management.

Earlier in her career, Dr. Malko was a family practitioner in Connecticut and Vermont, and a Senior Medical Director for MedSpan in Hartford, Conn. She received her Doctor of Medicine from the University of Connecticut School of Medicine and a master's degree in engineering from Rensselaer Polytechnic Institute.

Dr. Malko is a member of the Academy of Family Physicians and American College of Physicians and had previously been a Clinical Assistant Professor for the University of Connecticut School of Medicine. ●

new fchp appointments in network development

Eric Hall, who has served on an interim basis, has officially assumed the position of Vice President of Network Development and Management. Hall has played a major role in significantly growing the FCHP network, while also strengthening the health plan's relationships with the provider community. He has more than 16 years of experience in the managed care industry and previously held the position of Senior Director of Network Development and Contracting at FCHP. He received his bachelor's degree in economics from Framingham State College.



FCHP has appointed **Patrick W. Donahue** to Senior Director of Network Development and Contracting. He will manage the expansion of the FCHP provider network of physicians, hospitals and ancillary health providers.

Donahue comes to FCHP with more than 32 years of experience in health care administration and health finance. Most recently, he was Corporate Director of Managed Care for the Caritas Christi Health Care system.



continued, page 2

He is a graduate of the University of Massachusetts, where he obtained a bachelor's degree in finance and business operations, and a master's degree in business administration. ●

FCHP also has named **Kathy Bien** as Director of Provider Relations. Kathy has been a contract manager with the health plan for nearly seven years. She held previous positions as a Provider Relations Consultant and Senior Regional Business Consultant. Kathy's responsibilities as director include overseeing the Provider Appeals Department as well as the Internal and External Provider Relations Representatives. She has a bachelor's degree in business administration and marketing from the University of Massachusetts, and a master's degree in business administration from Assumption College. ●



to our masshealth providers

Beginning November 30, 2008, Fallon Community Health Plan, in conjunction with its behavioral health partner, Beacon Health Strategies, will require a uniform behavioral health assessment process. This will include a comprehensive needs assessment employing the Child Adolescent Needs and Strengths (CANS) tool.

The mandate to use the CANS tool is consistent with the Commonwealth's plan under the newly-formed Children's Behavioral Health Interagency Initiative to more reliably identify the behavioral health needs of MassHealth members under the age of 21. The CANS tool provides a standardized way to organize information gathered during the comprehensive clinical evaluation that is part of a behavioral health assessment. The CANS is intended to be used as a treatment decision support tool.

By November 30, 2008, clinicians who provide behavioral health assessment and treatment to MassHealth members under the age of 21 in certain levels of care must be trained and certified in the use of CANS.

More information about these requirements is available in the related provider letter on our Web site, www.fchp.org. Please see the "Physicians and providers" section, click on *Provider Manual*, then "FCHP products," and "Medicaid/MassHealth." ●

let's connect!

chiropractic coverage for commonwealth care members

Effective July 1, 2008, FCHP members covered under Commonwealth Care will no longer be eligible for chiropractic benefits. Please do not refer Commonwealth Care members for chiropractic visits after July 1, 2008. Should you have any questions, please call the provider service line at 1-866-ASK-FCHP, option 4. ●

reminder about sending phi

We'd like to remind you that sending PHI (personal health information), which is any information or data about one of our members, is not secure via e-mail. We do not send, or accept transmissions of, PHI by e-mail.

Instead, please communicate with us via fax transmissions when you need to send PHI. We have policies and procedures in place to monitor the security of these transmissions and ensure that member information is kept private and confidential. We also suggest you limit the content to the minimum necessary information. Thank you. ●

billing bytes

claimcheck[®] software upgrade

In order for Fallon Community Health Plan to be up to date with new technology, we continually evaluate our software and make modifications to accommodate our payment methodology.

With this in mind, FCHP is upgrading ClaimCheck to version 41. This software is an automated method that helps us in the proper processing of claims and ensures consistent application of FCHP payment policies across all claims. Due to the upgrade, you may see changes in reimbursement. If you have any questions, please contact Provider Relations at 1-866-ASK-FCHP, press 4. ●

code updates

Please note the following code changes:

Effective September 1, 2008, the following codes *will require plan preauthorization*.

G0248	Demonstration, use of home INR monitor
G0249	Provide testing material and equipment for home INR monitor
G0250	MD review and interpretation of home testing INR results
L3030	Foot insert, removable, formed to patient foot, each
L3140	Foot, abduction rotation bar, including shoes
L3160	Foot, adjustable shoe-styled positioning device
L3203	Orthopedic shoe, Oxford with supinator or pronator, child
L3230	Orthopedic footwear, custom shoe, depth inlay, each
L3260	Surgical boot/shoe, each
L3300	Lift, elevation, heel, tapered to metatarsals, per inch
L3332	Lift, elevation, inside shoe, tapered, up-to one-half inch
L3340	Heel wedge, SACH
L3350	Heel wedge
L3485	Heel pad, removable for spur
L3510	Orthopedic, shoe addition, insole, rubber
Q4096	Injection, von Willebrand factor complex, human, ristocetin cofactor (not otherwise specified), per i.u. VWF:RCo
Q4097	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg
Q4098	Injection, iron dextran, 50 mg
Q4099	Formoterol fumarate, inhalation solution, FDA approved final product, non-compounded, administered through DME, unit dose form, 20 micrograms

Effective immediately, the following codes *no longer require plan preauthorization*.

11900	Injection, intralesional; up to and including seven lesions
11901	Injection, intralesional; more than 7 lesions

Effective immediately, the following codes *are covered for all plan types*.

A5510	For diabetics only, direct formed, compression molded to patient foot without external heat source, multiple-density insert(s) prefabricated, per shoe
L3030	Foot insert, removable, formed to patient foot, each
V2600	Hand held low vision aids and other non-spectacle mounted aids
V2610	Single lens spectacle mounted low vision aids
V2615	Telescopic and other compound lens system, including distance vision telescopes and compound microscopic lens system

Effective September 1, 2008, the following codes *will no longer be separately reimbursed*.

A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips
A4256	Normal, low and high calibrator solution/chips

A4258	Spring-powered device for lancet, each
A4259	Lancets, per box of 100
E0607	Home blood glucose monitor
E2100	Blood glucose monitor with integrated voice synthesizer
E2101	Blood glucose monitor with integrated lancing/blood sample
S3628	Placement alpha microglobulin-1 rapid immunoassay for detection of rupture of membranes

Effective September 1, 2008, the following code is not covered for all plan types.

S9434	Modified solid food supplements for inborn errors of metabolism ●
-------	-------------------------------------------------------------------



● script alert

formulary updates

Fallon Community Health Plan often makes changes to its formularies, including changing prior authorization requirements and adding new medications. Please see these changes below to our commercial plan and Medicare Part D formularies.

commercial plan formulary

additions

CNL8 (ciclopirox) Nail Kit	Tier 3, 1 Kit = 90 day supply
Flector (diclofenac transdermal)	Tier 3, PA required
Luvox CR (fluvoxamine)	Tier 3, QLL
Millipred (prednisolone)	Tier 3
Patanase (olopatadine)	Tier 3
Salkera (salicylic acid)	Tier 3
Somatuline (lanreotide)	Tier 3, PA required
Tasigna (nilotinib)	Tier 3, PA required
Treximet (sumatriptan/naproxen)	Tier 3, PA required, QLL

changes

Restasis (cyclosporine)	QLL added
Zofran (ondansetron)	QLL increased

new to market policy*

Arcalyst (rilonacept)
Pristiq (desvenlafaxine)

* FCHP's New to Market Policy was enacted to ensure patient safety and to allow for adequate time for the development, review and approval of clinical criteria. When a new medication first becomes available, it will fall under this policy and be excluded from coverage. A process is in place that allows for the quick review of provider requests for non-covered pharmaceuticals.

continued, page 5

medicare part d formulary

additions

alendronate sodium 10mg tabs	Added as Tier1 QL 30 per 30 days	Oxycontin 15mg tb12	Added as Tier3 PA, QL 60 per 30 days
alendronate sodium 35mg tabs	Added as Tier1 QL 4 per 30 days	Oxycontin 30mg tb12	Added as Tier3 PA, QL 60 per 30 days
alendronate sodium 40mg tabs	Added as Tier1 QL 30 per 30 days	Oxycontin 60mg tb12	Added as Tier3 PA, QL 60 per 30 days
alendronate sodium 5mg tabs	Added as Tier1 QL 30 per 30 days	pantoprazole sodium 20mg tbec	Added as Tier2 QL 30 per 30 days
alendronate sodium 70mg tabs	Added as Tier1 QL 4 per 30 days	pantoprazole sodium 40mg tbec	Added as Tier2 QL 30 per 30 days
Avandaryl 2mg; 8mg tabs	Added as Tier2	pHisoHex 3% liqd	Added as Tier3
Avandaryl 4mg; 8mg tabs	Added as Tier2	Ramipril 10mg caps	Added as Tier1
balsalazide disodium 750mg caps	Added as Tier1	Ramipril 2.5mg caps	Added as Tier1
cefepime 1gm solr	Added as Tier1 PA	Ramipril 5mg caps	Added as Tier1
cefuroxime axetil 125mg/5ml susr	Added as Tier1	Ranexa 1000mg tb12	Added as Tier2 PA
cefuroxime axetil 250mg/5ml susr	Added as Tier1	Renvela 800mg tabs	Added as Tier3
Chantix 0 misc	Added as Tier3	Sanctura XR 60mg cp24	Added as Tier3
Combigan 0.2%; 0.5% soln	Added as Tier3	Selzentry 150mg tabs	Added as Tier3
Cortenema 100mg/60ml enem	Added as Tier3	Selzentry 300mg tabs	Added as Tier3
diclofenac sodium 0.1% soln	Added as Tier1	Simcor 1000mg; 20mg tb24	Added as Tier3 QL 30 per 30 days
Dilaudid 2mg tabs	Added as Tier3	Simcor 500mg; 20mg tb24	Added as Tier3 QL 30 per 30 days
Dilaudid 4mg tabs	Added as Tier3	Simcor 750mg; 20mg tb24	Added as Tier3 QL 30 per 30 days
famciclovir 125mg tabs	Added as Tier1	Soriatane ck 10mg; 0; 0 kit	Added as Tier2
famciclovir 250mg tabs	Added as Tier1	Soriatane ck 25mg; 0; 0 kit	Added as Tier2
famciclovir 500mg tabs	Added as Tier1	Suprax 200mg/5ml susr	Added as Tier3
FazaClo 12.5mg tbdp	Added as Tier3	Symbyax 25mg; 3mg caps	Added as Tier3
Fenoglide 120mg tabs	Added as Tier3	SymlinPen 120 1000mcg/ml soln	Added as Tier3 PA
Fenoglide 40mg tabs	Added as Tier3	SymlinPen 60 1000mcg/ml soln	Added as Tier3 PA
granisetron hcl 1mg tabs	Added as Tier1 PA	Tamiflu 30mg caps	Added as Tier3 PA
Granisol 2mg/10ml soln	Added as Tier1 PA	Tamiflu 45mg caps	Added as Tier3 PA
Intelence 100mg tabs	Added as Tier3	Tekturna HCT 150mg; 12.5mg tabs	Added as Tier3 PA
Iquix 1.5% soln	Added as Tier3	Tekturna HCT 150mg; 25mg tabs	Added as Tier3 PA
Kadian 10mg cp24	Added as Tier3	Tekturna HCT 300mg; 12.5mg tabs	Added as Tier3 PA
Kaletra 100mg; 25mg tabs	Added as Tier2	Tekturna HCT 300mg; 25mg tabs	Added as Tier3 PA
Lantus SoloStar 100unit/ml soln	Added as Tier3 PA	Thalomid 150mg caps	Added as Tier2 PA
Lexiva 50mg/ml susp	Added as Tier3	theophylline ER 400mg tb24	Added as Tier1
Lipofen 150mg caps	Added as Tier3	theophylline ER 600mg tb24	Added as Tier1
Lipofen 50mg caps	Added as Tier3	Trezix 356.4mg; 30mg; 16mg caps	Added as Tier1 ●
methylprednisolone 16mg tabs	Added as Tier1		
methylprednisolone 32mg tabs	Added as Tier1		
Nutropin AQ pen 20mg/2ml soln	Added as Tier3 PA		

have you seen your
connection?

Please pass this along to
the next person on the list.

Date received _____

Please route to:

- Office manager
- Physician
- Billing department
- Receptionist
- Referral site
- Other

● get connected ●●●

connection online • july 2008

There are no supplemental articles or policies this issue. ●

Connection is a bimonthly publication for all FCHP ancillary and affiliated providers. The next copy deadline is July 7, 2008.

Send information to
Kathleen M. Bien
Director, Provider Relations
Fallon Community Health Plan
10 Chestnut St., Worcester, MA 01608
e-mail: kathy.bien@fchp.org

Eric H. Schultz
President and CEO

Elizabeth Malko, M.D.
Chief Medical Officer

Eric Hall
Vice President, Network Development
and Management

www.fchp.org

questions?
1-866-ASK-FCHP